GlassScriptPhysician profile
Sidra Yunas
NPI 1689921447
$3,120.20
in general payments reported to CMS, 2019-2025
29 companies · $727 in 2025
The $727 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $367 · 2021: $286 · 2022: $179 · 2023: $803 · 2024: $313 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.07 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $436.24 | 2019-2023 | |
| Astellas Pharma US INC | $409.13 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $291.14 | 2023-2025 | Myfembree |
| Abbvie INC. | $278.30 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $184.85 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $177.53 | 2019-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Novasure |
| Evofem Biosciences, INC. | $169.22 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sage Therapeutics, LLC | $156.93 | 2019-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $136.30 | 2023 | |
| Medtronic, INC. | $122.65 | 2025 | V-Loc 180 |
| Lupin INC. | $104.23 | 2019-2021 | |
| Shield Therapeutics INC | $95.61 | 2023-2025 | Accrufer |
| Organon LLC | $71.60 | 2023-2025 | Nexplanon |
| Therapeuticsmd, INC. | $71.53 | 2019-2021 | |
| Allergan, INC. | $59.06 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renovia INC | $58.37 | 2019 | |
| Coopersurgical, INC. | $39.96 | 2023-2024 | Paragard T 380a, Endosee |
| Avion Pharmaceuticals | $34.36 | 2023 | Balcoltra |
| Novo Nordisk INC | $30.25 | 2019-2023 | Wegovy, Saxenda |
| Biogen, INC. | $26.74 | 2024 | Zurzuvae |
| Aspira Women'S Health INC | $24.65 | 2019-2024 | Ova1 |
| Duchesnay USA Incorporated | $24.11 | 2019 | |
| Merck Sharp & Dohme LLC | $22.49 | 2021 | |
| Medinc of Texas | $19.85 | 2025 | |
| Millicent US INC | $19.33 | 2020 | |
| Medicem INC. | $14.93 | 2020 | |
| Olympus America INC. | $14.34 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.53 | 2019 | |
| Gynesonics, INC. | $12.97 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidra Yunas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.